SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Babe Didrikson Zaharias — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMildred Ella Didrikson Zaharias
Date of birth1911-06-26
IdentifiersMRN HR-ML038-SYN-TD; SSN (made up) 000-38-4471
Document date1953-04-27
AuthorRosalind Vasquez-Thornbury, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Day 1 of cycle 2 of dostarlimab. [S]

History of Present Illness

Ms. Didrikson Zaharias comes before her second dose of dostarlimab. The first dose three weeks ago caused no reaction. Within ten days the bleeding became occasional streaks, and for the last week there has been none; her stools are a normal shape and the urgency has eased. She has had no diarrhea, rash, cough, breathlessness, headache or thirst. She has taken ferrous sulfate every other morning for four weeks, with mild constipation that settled with more fruit, and she is less tired. She is practicing every day and played 18 holes twice last week. The germline panel was negative, and tumor sequencing found two changes in MSH2 in the tumor itself, which explains the mismatch repair deficiency. She asked what this means for her brothers and sisters. [S]

ElementDetail
TreatmentDostarlimab cycle 1 three weeks ago; cycle 2 today
SymptomsNo bleeding for a week; normal stools; less tired
Adverse eventsNone
Genetic resultsGermline panel negative; two somatic MSH2 variants in the tumor

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy better; no fever; weight 63.2 kg
GastrointestinalNegativeNo bleeding for a week; no diarrhea or abdominal pain; mild constipation from iron, settled
IntegumentaryNegativeNo rash or itching
RespiratoryNegativeNo cough or breathlessness
EndocrineNegativeNo heat or cold intolerance, thirst or headache
PsychiatricNegativeHopeful; PHQ-9 4; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morningOne tablet every other morningOral route1953-03-30activeS
Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months)500 mg every 3 weeks for nine dosesIntravenous route1953-04-06 to 1953-09-21completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1953-04-27Body height168cmS
1953-04-27Body weight63.2kgS
1953-04-27Body mass index (BMI) [Ratio]22.4kg/m2S
1953-04-27Systolic blood pressure110mm[Hg]S
1953-04-27Diastolic blood pressure68mm[Hg]S
1953-04-27Heart rate70/minS
1953-04-27Respiratory rate14/minS
1953-04-27Body temperature36.6CelS
1953-04-27Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1953-04-27Hemoglobin [Mass/volume] in Blood12.1g/dL12-15.5 g/dLNormalS
1953-04-27MCV [Entitic mean volume] in Red Blood Cells by Automated count80fL80-100 fLNormalS
1953-04-27Leukocytes [#/volume] in Blood by Automated count6.210*3/uL4-11 10*3/uLNormalS
1953-04-27Platelets [#/volume] in Blood by Automated count35210*3/uL150-400 10*3/uLNormalS
1953-04-27Creatinine [Mass/volume] in Serum or Plasma0.74mg/dL0.59-1.04 mg/dLNormalS
1953-04-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M104mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1953-04-27Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
1953-04-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
1953-04-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-35 U/LNormalS
1953-04-27Thyrotropin [Units/volume] in Serum or Plasma2.2m[IU]/L0.45-4.5 mIU/LNormalS
1953-04-27Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
1953-04-27Carcinoembryonic Ag [Mass/volume] in Serum or Plasma3.4ng/mLUp to 3.0 ng/mL in non-smokersHighS
1953-04-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 1953-04-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 63.2 kg; blood pressure 110/68, pulse 70
SkinNo rash
NeckThyroid not enlarged or tender
AbdomenSoft, non-tender
RectalWith her agreement and a chaperone: the mass is smaller and softer, with a flatter edge; no blood on the glove

Problems

ProblemClinical statusVerificationCodeProvenance
Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this weekresolvedconfirmed K62.5S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tirednessactiveconfirmed D50.0S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season.
Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactlyactiveconfirmed C20S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood countBefore each dose of dostarlimab and at each visit; about four weeks after oral iron startsCompleted todayFour weeks after oral iron: hemoglobin 12.1 g/dL, MCV 80 fL, white cells 6.2, platelets 352
LaboratoryKidney and liver function and glucoseBefore each dose of PD-1 blockadeCompleted todayCreatinine 0.74 mg/dL, eGFR 104; ALT 22 U/L, AST 24 U/L; glucose 92 mg/dL
LaboratoryTSH and free T4At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine changeCompleted todayTSH 2.2 mIU/L, free T4 1.2 ng/dL
LaboratoryCEADuring treatment, as a marker of responseCompleted today3.4 ng/mL, down from 5.8
ExaminationDigital rectal examinationAt each oncology visit during treatment; every three to four months in watch-and-waitCompleted todayMass smaller and softer; no blood
ExaminationImmune-related adverse event review (diarrhea, rash, cough, breathlessness, fatigue, endocrine symptoms)Before each doseCompleted todayNone
LaboratoryGermline multigene panel and tumor sequencingGermline result before treatment decisions that depend on it; tumor sequencing when the germline panel is negativeCompleted todayGermline negative; two somatic MSH2 variants in the tumor; KRAS, NRAS and BRAF wild type
Self-managementScreening advice for first-degree relativesOnce the genetic results are knownCompleted todayColonoscopy from 40, or 10 years before her age at diagnosis if earlier, every five years; letter given for her to share as she chooses
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore systemic cancer treatmentUp to dateAll negative; hepatitis B surface antibody negative, so vaccination is due
LaboratoryFerritin after oral ironAbout three months after startingDueDue at the restaging visit
ImagingRestaging pelvic MRI and flexible sigmoidoscopyAbout every three months during treatmentDueBooked for the week before cycle 5
SurveyDistress and depression screen (PHQ-9, GAD-7)At diagnosis, at each treatment phase, and at least yearlyCompleted todayPHQ-9 4; item 9 scored 0
Self-managementPhysical activity and sportEach visitCompleted todayPlaying 18 holes and practicing daily

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Tung N, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol 2024;42(21):2599-2615 (PMID 38759122) (2024); Rex DK, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112(7):1016-1030 (PMID 28555630) (2017); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026)

Follow-up: Cycles 3 and 4 as booked; restaging MRI and sigmoidoscopy in about eight weeks; primary care review at cycle 5. Next scheduled visit 1953-06-29: restaging after four doses: pelvic MRI and endoscopy, immune-related hypothyroidism, and the decision to continue PD-1 blockade. [S]